RNTXRein Therapeutics Inc.

Sign up free

Market reactionShares fell 10% on Nov 5.

IntactLast material event Sep 4, 2026 · Updated Oct 25, 2026

Rein's inhaled LTI-03 reports interim Phase 2 data in IPF in late 2026

Rein Therapeutics is a clinical-stage company developing LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis, a scarring lung disease. It has no approved products.

Rein's case rests on LTI-03, an inhaled seven-amino-acid peptide that mimics part of caveolin-1, a protein lost in fibrotic lungs. In a Phase 1b trial both doses were well tolerated, and five exploratory biomarkers moved favorably at the higher dose. The Phase 2 RENEW trial plans to enroll about 120 patients, with interim data due in the fourth quarter of 2026. A $57.5 million offering in May funds RENEW to completion. Cash is expected to last into the first quarter of 2028.

Thesis checklist

0 risks need attention

Select a row for evidence
RENEW interim data show LTI-03 is active in IPFAwaiting evidenceNext: RENEW interim data (fourth quarter of 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash funds RENEW to completionSupportedNext: Q3 2026 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

RENEW Phase 2 interim data

Tests: RENEW interim data show LTI-03 is active in IPF

Fourth quarter of 2026

Does LTI-03 show early signs of slowing lung function decline, with acceptable safety, versus placebo?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
+5.3%Sep 4, 2026

Rein's inhaled LTI-03 reports interim Phase 2 data in IPF in late 2026

ChallengedFinancial
-24.0%May 4, 2026

LTI-03's RENEW Phase 2 interim data will determine whether Rein's inhaled anti-fibrotic can demonstrate meaningful efficacy in IPF

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Quick answers

Is the Rein Therapeutics (RNTX) investment thesis intact?
Yes. Readouts currently rates the Rein Therapeutics Thesis Intact. Rein's inhaled LTI-03 reports interim Phase 2 data in IPF in late 2026.
What is the next catalyst for Rein Therapeutics (RNTX)?
The next dated event is Phase 2 interim results (RENEW) for LTI-03, expected Q4 2026, as stated by the company.
How long will Rein Therapeutics' cash last?
Rein Therapeutics has said its cash will fund operations into the first quarter of 2028 (guidance as of August 14, 2026).

Other companies we cover in these diseases

Idiopathic pulmonary fibrosis
Contineum Therapeutics (CTNM)

Disease areas: Lung and respiratory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

5 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.